News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Dominion Energy beat Q2 estimates as hyperscale data-center demand lifted Virginia revenue, while costs rose and the $66.8B NextEra merger advances to hearings.
  • President Trump said U.S. pressure on the ICC aims to protect Netanyahu and others, raising geopolitical risk for U.S. diplomacy.
  • The administration plans diplomatic pressure, travel bans and sanctions targeting the International Criminal Court.
  • Italy suspended Schengen passport-free travel with Spain after a Ceuta migrant surge, and Spain says most of the 50,000 who crossed returned voluntarily.
  • Nasdaq corrected Alpha Compute's outstanding share count to 72,845,260, realigning its market-cap data.

Latest Articles

Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone

Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone

Nexentis Technologies, through its subsidiary MitoCareX Bio, has achieved a significant drug discovery milestone by optimizing a hit molecule targeting mitochondrial SLC25 carrier proteins, which are involved in difficult-to-treat cancers and inflammatory metabolic diseases. The milestone validates the MITOLINE® platform's capability to overcome st…

Quaest Poll Shows Lula and Flavio Bolsonaro Neck-and-Neck Ahead of October Runoff

Quaest Poll Shows Lula and Flavio Bolsonaro Neck-and-Neck Ahead of October Runoff

A new Quaest survey, commissioned by brokerage Genial and conducted May 8-11 with 2,004 respondents, indicates a statistical tie between President Luiz Inacio Lula da Silva and Senator Flavio Bolsonaro in a simulated runoff. The poll places Lula at 42% and Bolsonaro at 41% in a second-round matchup, while a first-round scenario shows Lula leading w…

Anfield Energy Completes Drilling of Monitoring Wells at Shootaring Canyon Mill and Slick Rock Mine Complex

Anfield Energy Completes Drilling of Monitoring Wells at Shootaring Canyon Mill and Slick Rock Mine Complex

Anfield Energy Inc. has successfully completed drilling monitoring wells at its Shootaring Canyon Mill in Utah and Slick Rock Mine Complex in Colorado. This development supports environmental oversight and operational readiness as the company advances its hub-and-spoke strategy to restart and expand uranium and vanadium production. The announcement…

Highlander Silver Appoints Poonam Puri to Board of Directors

Highlander Silver Appoints Poonam Puri to Board of Directors

Highlander Silver Corp. announced the appointment of Ms. Poonam Puri, an expert in corporate law and governance, to its Board of Directors as an independent director. Ms. Puri brings vast experience that will aid the company in accelerating development across its high-quality silver assets portfolio, including projects in Peru and Mexico.

Seer Files Patent Infringement Lawsuit Against Nanomics

Seer Files Patent Infringement Lawsuit Against Nanomics

Seer, Inc., a Nasdaq-listed company specializing in deep proteomic insights, has filed a patent infringement lawsuit against Nanomics Biotechnology, asserting that Nanomics' products infringe on several of Seer's U.S. patents related to nanoparticle protein enrichment. The company emphasizes the strength and robustness of its intellectual property …

Colliers Announces Normal Course Issuer Bid

Colliers Announces Normal Course Issuer Bid

Colliers International Group Inc. has initiated a new normal course issuer bid (NCIB) enabling the company to repurchase up to 4.3 million subordinate voting shares, approximately 10% of its public float, from May 2026 to May 2027. This move reflects Colliers’ confidence in its share value and commitment to enhancing shareholder value. All repurcha…

CTW Announces Financial Results for First Half of Fiscal 2026

CTW Announces Financial Results for First Half of Fiscal 2026

CTW reported a 1% decline in revenue to $40.9 million for the first half of fiscal 2026 compared to the prior year period. Despite modest revenue softness due to underperformance of new game launches and lifecycle trends in legacy titles, the company achieved a 55% increase in segment profit and 16% rise in Adjusted EBITDA by optimizing marketing s…

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing novel FASN inhibitors for metabolic and fibrotic diseases, announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference with a fireside chat scheduled on May 19, 2026. The event will be webcast and archived for investors and me…

OIO Group Enters into Term Sheet for Proposed Strategic Acquisition of German Specialist Automotive Engineering and Production Platform

OIO Group Enters into Term Sheet for Proposed Strategic Acquisition of German Specialist Automotive Engineering and Production Platform

OIO Group announced it has entered into a term sheet for the proposed acquisition of a privately held German automotive engineering and low-volume production platform. The acquisition aims to strengthen OIO's engineering depth, prototype capability, and operational infrastructure in Europe, supporting the ongoing development and production of the D…

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

Can-Fite BioPharma Ltd. announced advancement of its pancreatic cancer drug Namodenoson into a Phase 2b study combining it with immunotherapy. This follows encouraging Phase 2a data showing favorable safety and clinical activity in advanced pancreatic adenocarcinoma patients. The company plans to discuss study design and partnership negotiations at…

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics, a clinical-stage biopharmaceutical company specializing in targeted protein degradation therapies, announced that CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference and the Jefferies Global Healthcare Conference in May and June 2026. These events are opportunities for Nurix to present …

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

BioCryst Pharmaceuticals announced new real-world data presentations at ISPOR 2026 highlighting the significant healthcare resource utilization and quality-of-life impact of hereditary angioedema (HAE) on pediatric patients and their caregivers. The studies underscore ongoing unmet needs and the importance of optimized disease management in this ra…

Kornit Digital Reports First Quarter 2026 Results

Kornit Digital Reports First Quarter 2026 Results

Kornit Digital Ltd. announced its Q1 2026 results with revenues of $48.5 million at the top end of guidance, a 103% increase in All-Inclusive Click (AIC) revenues year-over-year, and positive operating cash flow for the tenth consecutive quarter. The company highlighted strong traction in digital fashion and textile production driven by product inn…

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

PDS Biotechnology Corporation announced its first quarter 2026 financial results and clinical updates, highlighting progress in its immunotherapy clinical trials including amendments to the VERSATILE-003 Phase 3 trial for HPV16-positive head and neck cancer and positive biomarker data from metastatic colorectal cancer and prostate cancer trials. Th…